Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICTALA for prevention of recurrent vulvovaginal candidiasis
ACTRN12620001084976Phase 2Completed
- Sponsor
- Griffith University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetic acid and lactic acid in recurrent vulvovaginal candidiasis (RVVC) (2 arms), sponsored by Griffith University. Primary endpoint: Recurrence and severity of recurrent vulvovaginal candidiasis. Started Jan 2021; status: completed.
02
Drugs
acetic acidlactic acid
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on ACTRN12620001084976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001084976.